Bayer Diabetes Care (JOBS) Statement on U.S. FDA Advice for Patients: Serious Errors with Certain Blood Glucose Monitoring Test Strips

Bookmark and Share

TARRYTOWN, N.Y., Aug. 13 /PRNewswire/ -- Since 2006, Bayer Diabetes Care has not distributed test strips that use GDH-PQQ (glucose dehydrogenase pyrroloquinoline quinone) glucose monitoring technology for its blood glucose meters. As referenced in a U.S. Food and Drug Administration Advice for Diabetic Patients and their Caregivers issued today, blood glucose meters that use GDH-PQQ technology may “produce a falsely high (elevated) blood glucose result.”

Bayer Diabetes Care is committed to patient safety and has a portfolio of blood glucose meters that all meet the current FDA requirements. The company adheres to and supports the highest standard of quality in its meters and strives to do everything possible by a manufacturer to ensure the accuracy of readings. Bayer Diabetes Care meters are designed to minimize the impact from as many external variants as possible, helping to ensure accuracy of readings. Bayer’s BREEZE®2 and CONTOUR® systems both feature No Coding(TM) technology, and no interference with common substances including the non-glucose sugars maltose and galactose.

For more information on Bayer Diabetes Care blood glucose monitoring systems, visit www.bayerdiabetes.com.

MORE ON THIS TOPIC